We conducted a study to examine the effectiveness of a specific iron supplement, emulsified microsomal ferric pyrophosphate (EMFP), in treating iron deficiency anemia among pregnant women. Our focus was not only on improving hemoglobin levels but also on alleviating related symptoms, including nausea.
Within 30 days of starting treatment with EMFP, we observed significant increases in hemoglobin levels, alongside marked improvements in serum ferritin and iron levels. As nausea is a common complaint among pregnant women, we noted a decrease in various symptoms, including nausea, breathlessness, and dizziness, which contributed to a better quality of life for the participants.
Notably, treatment compliance was remarkably high at 99.5%, indicating that the participants were committed to managing their anemia effectively. Importantly, we did not encounter any severe side effects related to the treatment, suggesting a favorable safety profile.
Overall, our findings support the idea that iron treatment can help alleviate nausea and other discomforts related to iron deficiency anemia in pregnancy, positively impacting both mother and baby.
Read More
FCH reduces nausea in IDA treatmentA Multicenter Single-Arm Study of Switching to Ferric Citrate Hydrate for Iron Deficiency Anemia in Patients Intolerant to Oral Iron: RIO-SWITCH.
High relevance for clinical practice
We evaluated how switching to ferric citrate hydrate (FCH) impacts nausea in women with iron deficiency anemia (IDA) who struggled with oral iron. In a multicenter study of 30 patients, those on FCH experienced significant improvements. Nausea scores dropped from 5.7 to 1.7, and the overall incidence of nausea decreased notably. Also, 80% reported better experiences compared to previous treatments.
Overall, our findings suggest that FCH not only enhances medication adherence but also effectively reduces nausea and improves quality of life in these patients.
Read More
We explored the role of vitamin B12 in treating nausea related to cerebral venous thrombosis (CVT). In a case study involving a 28-year-old man, we noted that after undergoing treatment with heparin, warfarin, and vitamin B12, his nausea improved along with his persistent headache symptoms.
Although we observed positive outcomes associated with this vitamin, it was part of a broader treatment approach rather than a standalone intervention. The study indicated that the combination of these treatments effectively alleviated nausea, but we cannot draw firm conclusions on vitamin B12's isolated impact due to the lack of control or blinding in the study design.
Overall, while vitamin B12 may have contributed to symptom relief, we must recognize that its specific role remains uncertain within the context of CVT treatment. Further studies would be needed to better define its effectiveness solely for nausea.
Read More
Daily vs. TIW iron supplementationDaily versus three times weekly dosing for treatment of iron deficiency nonanemia in NCAA Division 1 female athletes.
Moderate relevance to nausea effects
We explored the effects of daily versus three times weekly (TIW) oral iron supplementation on nausea in NCAA Division 1 female athletes. The study involved 33 athletes who were either in track and field or soccer. Participants were given either daily doses or TIW doses of ferrous bisglycinate over eight weeks.
Both groups showed an increase in serum ferritin levels, which is a marker of iron stores. However, the TIW regimen resulted in a smaller increase of about 5.17 μg/L, compared to an increase of 12.88 μg/L with the daily regimen. Notably, those taking daily supplements experienced significantly more nausea and constipation than those on the TIW schedule.
While the daily regimen may boost iron levels more effectively, it can come at the cost of increased gastrointestinal discomfort. Meanwhile, the TIW regimen offers a gentler option with fewer side effects, positioning it as a viable alternative for athletes concerned about nausea.
Read More
Ferric carboxymaltose reduces nauseaLow-dose ferric carboxymaltose vs. oral iron for improving hemoglobin levels in postpartum East Asian women: A randomized controlled trial.
Important findings on iron treatments.
This randomized controlled trial explored how low-dose ferric carboxymaltose (FCM) affects hemoglobin levels and nausea in postpartum East Asian women. Participants received either an intravenous FCM infusion or oral iron for four weeks.
We found that while FCM significantly increased hemoglobin levels after two weeks, both treatments showed no significant difference in final hemoglobin results after four weeks.
Notably, the FCM group experienced fewer gastrointestinal side effects, including nausea, suggesting it may be a more comfortable option for new mothers.
Read More